skip to Main Content
Recent News


Stay up to date on the latest news about Abpro, including press releases and upcoming publications.


Press Releases

SEP 21, 2023
Abpro to Become Publicly Traded via Merger with Atlantic Coastal Acquisition Corp. II
Read More →
SEP 21, 2022
Abpro Finalizes Strategic Partnership with Celltrion for Worldwide Development and Commercialization of a Cancer Treatment Bispecific Antibody
Read More →
DEC 9, 2021
Abpro Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron Variant
Read More →
MAY 4, 2021
Abpro Announces Presentation and Data at the 2021 Annual Association for Research in Vision and Ophthalmology of ABP201 for the Treatment of Wet Age-related Macular Degeneration
Read More →
FEB 2, 2021
Abpro Announces Positive Phase 1 Results Demonstrating A Favorable Safety and Pharmacokinetic Profile of ABP 300, A Neutralizing Antibody Therapeutic for the Treatment of COVID-19
Read More →
DEC 16, 2020
Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19
Read More →
NOV 25, 2020
Abpro Expands Scientific Advisory Board with the Addition of Infectious Disease Leaders
Read More →
NOV 16, 2020
Abpro Announces Peer-Reviewed Publication Demonstrating Efficacy of its Neutralizing Antibody Therapeutic Against COVID-19
Read More →
OCT 20, 2020
Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19
Read More →
MAR 3, 2020
Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian Markets
Read More →
FEB 28, 2019
Abpro and NJCTTQ Enter Into Partnership For Development of Multiple Novel Bispecific Antibodies
Read More →
NOV 29, 2016
Medimmune and Abpro Enter into A Collaborative Agreement For a Novel Bispecific Antibody
Read More →
OCT 13, 2016
GEN Roundup: Immunoassays: Life Science Critical Tools
Read More →
MAY 20, 2016
Abpro Announces Agreements with Two Boston Hospitals
Read More →
APR 25, 2016
Abpro Announces Investment and Partnership with Essex Bio
Read More →
OCT 10, 2014
Abpro Co-Founder Eugene Chan Wins Nokia Sensing XChallenge
Read More →


November 6, 2019
Abpro's TetraBi Platform for T-cell Engaging Antibodies targeting Claudin 18.2-expressing cancers Published for the 2019 SITC meeting
Read More →
MAY 16, 2019
Abpro's TetraBi Platform for T-cell Engaging Antibodies Published for the 2019 ASCO Meeting
Read More →
Back To Top